Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received a consensus recommendation of “Hold” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $20.80.
HALO has been the topic of several recent research reports. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Tuesday, January 15th. Cantor Fitzgerald set a $24.00 price target on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research report on Thursday, February 28th. BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. JMP Securities reaffirmed a “buy” rating and issued a $21.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 27th. Finally, TheStreet cut shares of Halozyme Therapeutics from a “c” rating to a “d” rating in a research report on Tuesday, March 5th.
Several institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its position in Halozyme Therapeutics by 12.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,601,604 shares of the biopharmaceutical company’s stock worth $65,441,000 after purchasing an additional 400,008 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Halozyme Therapeutics by 24.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 802,171 shares of the biopharmaceutical company’s stock worth $14,575,000 after purchasing an additional 158,349 shares during the last quarter. United Services Automobile Association increased its position in Halozyme Therapeutics by 112.4% in the 3rd quarter. United Services Automobile Association now owns 45,778 shares of the biopharmaceutical company’s stock worth $832,000 after purchasing an additional 24,228 shares during the last quarter. Deutsche Bank AG increased its position in Halozyme Therapeutics by 7.4% in the 3rd quarter. Deutsche Bank AG now owns 1,193,707 shares of the biopharmaceutical company’s stock worth $21,688,000 after purchasing an additional 82,245 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter worth about $616,000. 83.23% of the stock is currently owned by hedge funds and other institutional investors.
Shares of HALO traded up $0.03 during trading hours on Monday, hitting $16.57. The stock had a trading volume of 34,099 shares, compared to its average volume of 829,242. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.86 and a quick ratio of 2.71. The company has a market cap of $2.40 billion, a PE ratio of -29.54 and a beta of 1.85. Halozyme Therapeutics has a 1-year low of $13.24 and a 1-year high of $20.54.
Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, February 21st. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.02. Halozyme Therapeutics had a negative return on equity of 31.86% and a negative net margin of 52.90%. The company had revenue of $60.23 million during the quarter, compared to the consensus estimate of $59.77 million. During the same period last year, the business posted $0.85 EPS. The firm’s revenue for the quarter was down 68.2% compared to the same quarter last year. Analysts expect that Halozyme Therapeutics will post -0.43 EPS for the current fiscal year.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Recommended Story: How to interpret a stock’s beta number
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.